| Literature DB >> 20828384 |
Alemnesh H Mirkuzie1, Sven Gudmund Hinderaker, Odd Mørkve.
Abstract
BACKGROUND: Prevention of Mother-to-Child HIV Transmission (PMTCT) is still the most effective intervention in combating new HIV infections. In 2008, revised national PMTCT guidelines that incorporated new policies on HIV counselling and testing, antiretroviral prophylaxis regimen and infant HIV diagnosis came into effect in Ethiopia. In the present study we have examined trends in PMTCT service utilization and assessed the rate of MTCT in relation to policy changes in the national PMTCT programme.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20828384 PMCID: PMC2944274 DOI: 10.1186/1472-6963-10-267
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Figure 1Proportion of women who received pre-test counselling, testing and post-test counselling among new ANC attendees. --- In 2004 to 2007 when the HIV testing was offered in an opt-in approach. ___In 2008 and 2009 when the HIV testing was offered routinely in an opt-out approach.
Figure 2Trends in HIV prevalence among antenatal care attendees tested in PMTCT settings from 2004 to 2009 in Addis Ababa.
HIV prevalence among antenatal care attendees who tested for HIV, relative risk and χ2 for trend test across the years by sub-city
| Sub-city | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % (n) | RR | % (n) | RR | % (n) | RR | % (n) | RR | % (n) | RR | % (n) | RR | ||
| 12.8(195) | Ref | 11.1(168) | 0.99 | 7.4(170) | 0.66 | 7.8(231) | 0.70 | 4.6(178) | 0.41 | 4.7(130) | 0.42 | 127.3 * | |
| 8.7(99) | Ref | 7.0(131) | 0.81 | 6.8(16) | 0.78 | 4.9(136) | 0.57 | 5.3(113) | 0.61 | 22.3 * | |||
| 8.9(134) | Ref | 8.2(185) | 0.92 | 6.3(159) | 0.71 | 5.9(298) | 0.66 | 3.8(123) | 0.43 | 64.4 * | |||
| 8.6(89) | Ref | 10.0(112) | 1.17 | 6.8(149) | 0.79 | 5.5(158) | 0.64 | 4.8(171) | 0.56 | 3.2(130) | 0.37 | 105.4* | |
| 6.7(77) | Ref | 6.6(118) | 0.98 | 5.7(156) | 0.84 | 5.0(136) | 0.75 | 4.5(93) | 0.67 | 12.1** | |||
| 10.2(89) | Ref | 9.5(188) | 0.93 | 7.1(162) | 0.69 | 6.8(191) | 0.66 | 4.6(122) | 0.44 | 54.3 * | |||
| 5.4(67) | Ref | 4.9(75) | 0.91 | 2.8(70) | 0.51 | 3.3(73) | 0.62 | 3.7(81) | 0.69 | 7.7‡ | |||
| 9.6(148) | Ref | 10.2(244) | 1.06 | 6.8(198) | 0.71 | 5.9(228) | 0.62 | 4.8(246) | 0.50 | 4.6(217) | 0.48 | 119.8* | |
| 8.0(175) | Ref | 7.5(253) | 0.93 | 6.0(232) | 0.74 | 4.6(217) | 0.57 | 4.0(140) | 0.49 | 70.5* | |||
| 7.9(161) | Ref | 7.6(228) | 0.96 | 8.2(206) | 1.03 | 9.3(268) | 1.17 | 9.2(193) | 1.17 | 6.2‡ | |||
Ref = Reference *P < 0.0001 **P < 0,001 ‡P < 0,01 ‡ ‡ P < 0,05 NB: The denominator for each cell is different
Figure 3Percentage of women and babies who received ARV prophylaxis from 2004 to 2009 in Addis Ababa.
Figure 4HIV infection among exposed babies tested for HIV from 2006 to 2009 in Addis Ababa.
Figure 5Trends in partner testing in the PMTCT settings from 2004 to 2009 in Addis Ababa.